Publications by authors named "Timothy A Yap"

100Publications

Clinical Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance.

Cancer Discov 2020 Oct 22;10(10):1475-1488. Epub 2020 Jul 22.

The CRUK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-19-1485DOI Listing
October 2020

Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract.

Gynecol Oncol 2020 Sep 11;158(3):570-575. Epub 2020 Jun 11.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2020.05.682DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486997PMC
September 2020

PARP inhibition - opportunities in pancreatic cancer.

Nat Rev Clin Oncol 2019 10;16(10):595-596

Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0257-6DOI Listing
October 2019

Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy.

Cancer Cell 2019 06;35(6):851-867.e7

Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Cell, Development and Cancer Biology, Oregon Health and Sciences University, Portland, OR 97201, USA; Knight Cancer Institute, Portland, OR 97201, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2019.05.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642675PMC
June 2019

The DNA Damaging Revolution: PARP Inhibitors and Beyond.

Am Soc Clin Oncol Educ Book 2019 Jan 17;39:185-195. Epub 2019 May 17.

4 Weston Park Cancer Centre, Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_238473DOI Listing
January 2019

PARP Inhibitors: Extending Benefit Beyond -Mutant Cancers.

Clin Cancer Res 2019 07 13;25(13):3759-3771. Epub 2019 Feb 13.

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-0968DOI Listing
July 2019

Development of PARP and Immune-Checkpoint Inhibitor Combinations.

Cancer Res 2018 12 29;78(24):6717-6725. Epub 2018 Nov 29.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine; Khalifa Institute for Personalized Cancer Therapy; Department of Thoracic/Head and Neck Medical Oncology; The Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-54
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-18-2652DOI Listing
December 2018

Moving Precision Oncology Forward Amid Myths and Misconceptions.

JAMA Oncol 2018 12;4(12):1788-1789

Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2018.5064DOI Listing
December 2018

Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma.

Br J Cancer 2018 10 31;119(9):1118-1128. Epub 2018 Oct 31.

Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, SW7 3RP, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-018-0242-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219501PMC
October 2018

State-of-the-art strategies for targeting the DNA damage response in cancer.

Nat Rev Clin Oncol 2019 02;16(2):81-104

Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41571-018-0114-z
Publisher Site
http://dx.doi.org/10.1038/s41571-018-0114-zDOI Listing
February 2019

Combination drug development in BRAF mutant colorectal cancer.

Oncoscience 2018 Mar 29;5(3-4):51-53. Epub 2018 Apr 29.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), and the Department of Thoracic/Head and Neck Medical Oncology; Khalifa Institute for Personalized Cancer Therapy;The Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 455, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncoscience.399DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978439PMC
March 2018

Challenges with biomarkers in cancer drug discovery and development.

Expert Opin Drug Discov 2018 08 24;13(8):685-690. Epub 2018 May 24.

a Department of Investigational Cancer Therapeutics (Phase I Program) , The University of Texas MD Anderson Cancer Center , Houston , Texas , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17460441.2018.1479740DOI Listing
August 2018

Targeting the PI3K pathway in cancer: are we making headway?

Nat Rev Clin Oncol 2018 05 6;15(5):273-291. Epub 2018 Mar 6.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/doifinder/10.1038/nrclinonc.2018.28
Publisher Site
http://dx.doi.org/10.1038/nrclinonc.2018.28DOI Listing
May 2018

Efficacy and Toxic Effects of Cancer Immunotherapy Combinations-A Double-edged Sword.

JAMA Oncol 2018 08;4(8):1116-1117

Department of Investigational Cancer Therapeutics (Phase I Program), Department of Thoracic/Head and Neck Medical Oncology, Institute for Applied Cancer Science.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2017.4606DOI Listing
August 2018

Precision oncology: East meets West.

Int J Cancer 2018 05 4;142(9):1734-1737. Epub 2018 Jan 4.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.31218DOI Listing
May 2018

Precision Medicine: Progress, Pitfalls, and Promises.

Mol Cancer Ther 2017 12;16(12):2641-2644

The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-17-0904DOI Listing
December 2017

The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers.

J Clin Pharmacol 2018 04 26;58(4):474-484. Epub 2017 Nov 26.

Northern Centre for Cancer Care, Freeman Hospital, Freeman Road, High Heaton, Newcastle upon Tyne, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcph.1035DOI Listing
April 2018

Development of Molecularly Driven Targeted Combination Strategies.

Oncologist 2017 12 16;22(12):1421-1423. Epub 2017 Oct 16.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program) and Khalifa Institute for Personalized Cancer Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/lookup/doi/10.1634/th
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2017-0402DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728037PMC
December 2017

Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?

Lung Cancer 2017 09 15;111:6-11. Epub 2017 Jun 15.

Royal Marsden NHS Foundation Trust, London, United Kingdom; The Institute of Cancer Research, London, United Kingdom. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.06.005DOI Listing
September 2017

Novel insights into mesothelioma biology and implications for therapy.

Nat Rev Cancer 2017 07;17(8):475-488

University of Leicester, Leicester LE1 9HN, UK.

View Article

Download full-text PDF

Source
http://www.nature.com/doifinder/10.1038/nrc.2017.42
Publisher Site
http://dx.doi.org/10.1038/nrc.2017.42DOI Listing
July 2017

Targeting ATR in cancer medicine.

Curr Probl Cancer 2017 Jul - Aug;41(4):302-315. Epub 2017 May 17.

Drug Development Unit, Royal Marsden Hospital, London, UK; The Institute of Cancer Research, London, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.currproblcancer.2017.05.002DOI Listing
May 2017

Targeting -Mutant Colorectal Cancer: Progress in Combination Strategies.

Cancer Discov 2017 06;7(6):558-560

The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-17-0087DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458523PMC
June 2017

Circulating tumor DNA-From bench to bedside.

Curr Probl Cancer 2017 May - Jun;41(3):212-221. Epub 2017 Mar 1.

Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01470272173002
Publisher Site
http://dx.doi.org/10.1016/j.currproblcancer.2017.02.005DOI Listing
March 2018

Precision medicine in oncology.

Curr Probl Cancer 2017 May - Jun;41(3):163-165. Epub 2017 Jan 24.

The University of Texas MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics, Department of thoracic/head and neck medical oncology, Houston, TX.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01470272163020
Publisher Site
http://dx.doi.org/10.1016/j.currproblcancer.2017.01.001DOI Listing
March 2019

Extracranial Soft-Tissue Tumors: Repeatability of Apparent Diffusion Coefficient Estimates from Diffusion-weighted MR Imaging.

Radiology 2017 07 16;284(1):88-99. Epub 2017 Mar 16.

From the Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging (J.M.W., N.T., M.R., K.M., N.P.J., M.G., M.D.B., D.J.C., N.M.d.S., S.J.D., D.M.K., M.O.L., C.M., M.R.O.) and Division of Clinical Studies (J.S.d.B., T.A.Y.), the Institute of Cancer Research and Royal Marsden Hospital, London, England; MRI Unit (J.M.W., N.T., M.R., K.M., N.P.J., M.G., M.D.B., D.J.C., N.M.d.S., S.J.D., D.M.K., M.O.L., C.M., M.R.O.) and Drug Development Unit (J.S.d.B., T.A.Y.), the Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, England.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2017161965DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063352PMC
July 2017

Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.

Eur J Cancer 2017 05 6;76:52-59. Epub 2017 Mar 6.

Royal Marsden NHS Foundation Trust, Downs Road, London SM2 5PT, UK; The Institute of Cancer Research, Cotswold Road, London SM2 5NG, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.01.020DOI Listing
May 2017

Targeting the PD-1/PD-L1 axis in non-small cell lung cancer.

Curr Probl Cancer 2017 Mar - Apr;41(2):111-124. Epub 2016 Dec 23.

Lung Cancer Unit, Department of Medicine, Royal Marsden NHS Foundation Trust, London, UK; Royal Marsden NHS Foundation Trust, London, UK; Cancer Biomarkers, The Institute of Cancer Research, London, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.currproblcancer.2016.12.002DOI Listing
February 2018

Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.

Cancer Discov 2017 01 21;7(1):20-37. Epub 2016 Dec 21.

Royal Marsden NHS Foundation Trust, London, United Kingdom.

View Article

Download full-text PDF

Source
http://cancerdiscovery.aacrjournals.org/lookup/doi/10.1158/2
Publisher Site
http://dx.doi.org/10.1158/2159-8290.CD-16-0860DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300099PMC
January 2017

Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match?

J Thorac Oncol 2017 01;12(1):12-14

Royal Marsden Hospital, London, United Kingdom; National Heart and Lung Institute, Imperial College London, London, United Kingdom. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.10.019DOI Listing
January 2017

Emerging biomarkers for PD-1 pathway cancer therapy.

Biomark Med 2017 Jan 12;11(1):53-67. Epub 2016 Dec 12.

Drug Development Unit, Royal Marsden Hospital, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/bmm-2016-0228DOI Listing
January 2017

Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics.

Trends Pharmacol Sci 2017 01 18;38(1):25-40. Epub 2016 Nov 18.

The Institute of Cancer Research and Royal Marsden Hospital, Downs Road, London SM2 5PT, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tips.2016.10.012DOI Listing
January 2017

Emerging strategies for the treatment of advanced small cell lung cancer.

J Thorac Dis 2016 Oct;8(10):E1249-E1253

Royal Marsden Hospital, London, UK; ; The Institute of Cancer Research, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2016.10.46DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107470PMC
October 2016

Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer.

Eur J Cancer 2017 01 17;70:12-21. Epub 2016 Nov 17.

Department of Medicine, Royal Marsden Hospital, London, UK; Section of Genomic Medicine, National Heart and Lung Institute, Imperial College, London, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.10.014DOI Listing
January 2017

Combining Molecularly Targeted Agents: Is More Always Better?

Clin Cancer Res 2017 Mar 10;23(5):1123-1125. Epub 2016 Nov 10.

Royal Marsden Hospital, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-2399DOI Listing
March 2017

Immuno-oncology combinations: raising the tail of the survival curve.

Cancer Biol Med 2016 Jun;13(2):171-93

Drug Development Unit; Lung Unit, Royal Marsden Hospital and The Institute of Cancer Research, London SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://www.cancerbiomed.org/index.php/cocr/article/view/936
Publisher Site
http://dx.doi.org/10.20892/j.issn.2095-3941.2016.0015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944548PMC
June 2016

Drug discovery in advanced prostate cancer: translating biology into therapy.

Nat Rev Drug Discov 2016 10 22;15(10):699-718. Epub 2016 Jul 22.

The Institute of Cancer Research, 15 Cotswold Road, London SM2 5NG, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd.2016.120DOI Listing
October 2016

CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer.

Cancer Discov 2016 07;6(7):697-9

The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-16-0563DOI Listing
July 2016

Biopsy-Derived Biomarkers in Phase I Trials: Building Confidence in Drug Development.

J Clin Oncol 2016 07 2;34(20):2431-2. Epub 2016 May 2.

The Institute of Cancer Research, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.0075DOI Listing
July 2016

Development of molecularly targeted agents and immunotherapies in small cell lung cancer.

Eur J Cancer 2016 06 7;60:26-39. Epub 2016 Apr 7.

Lung Cancer Unit, Department of Medicine, Royal Marsden Hospital, London, United Kingdom; Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.03.004DOI Listing
June 2016

PARP inhibitors: the race is on.

Br J Cancer 2016 Mar;114(7):713-5

Drug Development Unit, Royal Marsden Hospital, London, UK.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/bjc201667
Publisher Site
http://dx.doi.org/10.1038/bjc.2016.67DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984871PMC
March 2016

A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients.

Cancer Chemother Pharmacol 2016 Feb 26;77(2):375-83. Epub 2015 Dec 26.

Department of Medicine, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2950-1DOI Listing
February 2016

Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials.

Transl Oncogenomics 2015 15;7(Suppl 1):1-11. Epub 2015 Nov 15.

Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/TOG.S30533DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648610PMC
November 2015

Drugging PI3K in cancer: refining targets and therapeutic strategies.

Curr Opin Pharmacol 2015 Aug 25;23:98-107. Epub 2015 Jun 25.

Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14714892150006
Publisher Site
http://dx.doi.org/10.1016/j.coph.2015.05.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728196PMC
August 2015

Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials.

Clin Cancer Res 2015 Apr 3;21(8):1869-76. Epub 2015 Feb 3.

Drug Development Unit, Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research and The Royal Marsden, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2424DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401558PMC
April 2015

Combining targeted therapeutics in the era of precision medicine.

Br J Cancer 2015 Jan;112(1):1-3

1] Division of Clinical Studies, The Institute of Cancer Research, Sutton, Surrey, UK [2] Drug Development Unit, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2014.558DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453608PMC
January 2015

Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer.

Pharmgenomics Pers Med 2014 19;7:285-95. Epub 2014 Sep 19.

Lung Cancer Unit, Department of Medicine, The Royal Marsden National Health Service Foundation Trust, London, United Kingdom ; National Heart and Lung Institute, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/PGPM.S55339DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4178554PMC
October 2014

Strategies for modern biomarker and drug development in oncology.

J Hematol Oncol 2014 Oct 3;7:70. Epub 2014 Oct 3.

Drug Development Unit, Royal Marsden NHS Foundation Trust, Division of Clinical Studies, The Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://jhoonline.biomedcentral.com/articles/10.1186/s13045-0
Publisher Site
http://dx.doi.org/10.1186/s13045-014-0070-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189730PMC
October 2014

Circulating tumor cells: a multifunctional biomarker.

Clin Cancer Res 2014 May;20(10):2553-68

Authors' Affiliations: Division of Clinical Studies, The Institute of Cancer Research; Drug Development Unit, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom; Kantonsspital St. Gallen, Department of Medical Oncology, Gallen, Switzerland; and Spanish National Cancer Research Centre, Madrid, SpainAuthors' Affiliations: Division of Clinical Studies, The Institute of Cancer Research; Drug Development Unit, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom; Kantonsspital St. Gallen, Department of Medical Oncology, Gallen, Switzerland; and Spanish National Cancer Research Centre, Madrid, Spain

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-2664DOI Listing
May 2014

The role of afatinib in the management of non-small cell lung carcinoma.

Expert Opin Drug Metab Toxicol 2013 Nov 28;9(11):1529-39. Epub 2013 Aug 28.

Royal Marsden NHS Foundation Trust , London , UK +44 20 7352 8171 ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/17425255.2013.832755DOI Listing
November 2013

Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study.

Clin Cancer Res 2013 Oct 6;19(19):5485-93. Epub 2013 Aug 6.

Authors' Affiliations: The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton; Edinburgh Cancer Research UK Center, Medical Research Council Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh; The Cancer Research UK Gene Function Laboratory; Breakthrough Breast Cancer Research Center; Tumour Profiling Unit, The Institute of Cancer Research, London, United Kingdom; University of California San Francisco, San Francisco, California; Department of Medical Oncology, Prince of Wales Clinical School, Prince of Wales Hospital, Sydney, Australia; The Chaim Sheba Medical Center, Tel Hashomer, Israel; Princess Margaret Hospital, Toronto, Canada; Oncologisch Centrum Vrije Universiteit Brussel, Brussels, Belgium; and Dana Farber Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1262DOI Listing
October 2013

Targeting the PI3K-AKT-mTOR signaling network in cancer.

Chin J Cancer 2013 May;32(5):253-65

The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5732/cjc.013.10057DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845556PMC
May 2013

Development of therapeutic combinations targeting major cancer signaling pathways.

J Clin Oncol 2013 Apr 18;31(12):1592-605. Epub 2013 Mar 18.

Royal Marsden National Health Service Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2013/03/18/JCO.2011.37
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2011.37.6418
Publisher Site
http://dx.doi.org/10.1200/JCO.2011.37.6418DOI Listing
April 2013

Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer.

Eur J Cancer 2013 Apr 19;49(6):1246-53. Epub 2012 Dec 19.

Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2012.11.016DOI Listing
April 2013

Cabazitaxel in metastatic castration-resistant prostate cancer.

Expert Rev Anticancer Ther 2012 Sep;12(9):1129-36

Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1586/era.12.88
Publisher Site
http://dx.doi.org/10.1586/era.12.88DOI Listing
September 2012

Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?

EPMA J 2012 Jan 12;3(1). Epub 2012 Jan 12.

Drug Development Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13167-011-0138-2
Publisher Site
http://dx.doi.org/10.1007/s13167-011-0138-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3375104PMC
January 2012

Targeting the DNA damage response in oncology: past, present and future perspectives.

Curr Opin Oncol 2012 May;24(3):316-24

Drug Development Unit, Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0b013e32835280c6DOI Listing
May 2012

Intratumor heterogeneity: seeing the wood for the trees.

Sci Transl Med 2012 Mar;4(127):127ps10

Department of Medicine, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.

View Article

Download full-text PDF

Source
http://stm.sciencemag.org/content/scitransmed/4/127/127ps10.
Web Search
http://stm.sciencemag.org/cgi/doi/10.1126/scitranslmed.30038
Publisher Site
http://dx.doi.org/10.1126/scitranslmed.3003854DOI Listing
March 2012

Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics.

Annu Rev Pharmacol Toxicol 2012 ;52:549-73

Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey SM2 5NG, United Kingdom.

View Article

Download full-text PDF

Source
http://www.annualreviews.org/doi/10.1146/annurev-pharmtox-01
Publisher Site
http://dx.doi.org/10.1146/annurev-pharmtox-010611-134532DOI Listing
May 2012

Opportunities and pitfalls of targeted therapeutic combinations in solid tumors.

Am Soc Clin Oncol Educ Book 2012 :670-4

From the Drug Development Unit, Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, Downs Road, Sutton, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2012.32.191DOI Listing
April 2016

Future directions in the evaluation of c-MET-driven malignancies.

Ther Adv Med Oncol 2011 Nov;3(1 Suppl):S51-60

Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1758834011423540
Publisher Site
http://dx.doi.org/10.1177/1758834011423540DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3225021PMC
November 2011

c-MET: an exciting new target for anticancer therapy.

Ther Adv Med Oncol 2011 Nov;3(1 Suppl):S3-5

Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1758834011423402
Publisher Site
http://dx.doi.org/10.1177/1758834011423402DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3225019PMC
November 2011

The changing therapeutic landscape of castration-resistant prostate cancer.

Nat Rev Clin Oncol 2011 Aug 9;8(10):597-610. Epub 2011 Aug 9.

Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2011.117DOI Listing
August 2011

HGF/c-MET targeted therapeutics: novel strategies for cancer medicine.

Curr Drug Targets 2011 Dec;12(14):2045-58

Royal Marsden NHS Foundation Trust and The Institute of Cancer Research Downs Road, Sutton, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/138945011798829348DOI Listing
December 2011

The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment.

Curr Drug Targets 2011 Dec;12(14):2034-44

The Royal Marsden NHS Foundation Trust, Downs Road Sutton, Surrey, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/138945011798829438DOI Listing
December 2011

Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies.

Expert Opin Investig Drugs 2011 Sep 22;20(9):1293-304. Epub 2011 Jul 22.

Drug Development Unit, Royal Marsden NHS Foundation Trust, Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2011.602630DOI Listing
September 2011

Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials.

Clin Cancer Res 2011 Aug 29;17(15):5188-96. Epub 2011 Apr 29.

Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-3019DOI Listing
August 2011